Who owns 4D Molecular Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of FDMT from SEC Form 13F filings across 167 reporting managers. All positions are from one synchronized reporting period — 2026-09-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-09-30 reporting period, 167 institutions disclosed 58.0M shares of 4D Molecular Therapeutics, Inc. worth $829.7M — about 80.3% of shares outstanding; the largest disclosed holder is Janus Henderson Group Ltd.. Source: SEC Form 13F filings, parsed by EvidInvest.
167
13F holders
$829.7M
value, 2026 filers
80.3%
of shares outstanding (58.0M sh)
31
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-09-30 · % of fund = share of the manager's own book · % of co. = share of FDMT's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | Janus Henderson Group Ltd.NEW | 5.7M | $81.9M | 0.0% | 7.9% | new |
| 2 | RA CAPITAL MANAGEMENT, L.P. | 5.0M | $72.3M | 0.7% | 7% | 0.0% |
| 3 | BlackRock, Inc. | 4.7M | $67.6M | 0.0% | 6.5% | +3.9% |
| 4 | GOLDMAN SACHS GROUP INC | 3.9M | $56.2M | 0.0% | 5.4% | -7.7% |
| 5 | NOVO HOLDINGS A/S | 3.0M | $42.9M | 2.9% | 4.2% | -7.7% |
| 6 | BVF INC/IL | 2.9M | $41.2M | 1.4% | 4% | 0.0% |
| 7 | STATE STREET CORP | 2.5M | $35.3M | 0.0% | 3.4% | -15.2% |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 2.3M | $32.8M | 0.0% | 3.2% | +1.8% |
| 9 | T. Rowe Price Investment Management, Inc. | 2.3M | $32.4M | 0.0% | 3.1% | -9.8% |
| 10 | Trails Edge Capital Partners, LP | 2.2M | $31.9M | 4.6% | 3.1% | 0.0% |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $30.6M | 0.0% | 3% | +2.0% |
| 12 | ARMISTICE CAPITAL, LLC | 1.9M | $27.9M | 0.3% | 2.7% | -2.5% |
| 13 | BANK OF AMERICA CORP /DE/ | 1.5M | $22.0M | 0.0% | 2.1% | +37.0% |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 1.2M | $17.0M | 0.0% | 1.6% | +4.9% |
| 15 | MORGAN STANLEY | 1.1M | $15.6M | 0.0% | 1.5% | +116.8% |
| 16 | Evergreen Quality Fund GP, Ltd. | 951,474 | $13.6M | 0.2% | 1.3% | 0.0% |
| 17 | DIMENSIONAL FUND ADVISORS LP | 787,000 | $11.3M | 0.0% | 1.1% | +7.7% |
| 18 | Parkman Healthcare Partners LLC | 772,177 | $11.0M | 1.0% | 1.1% | -18.6% |
| 19 | Catalio Capital Management, LP | 684,753 | $9.8M | 1.8% | 0.9% | +45.3% |
| 20 | VANGUARD PORTFOLIO MANAGEMENT LLC | 578,930 | $8.3M | 0.0% | 0.8% | -0.2% |
| 21 | DEUTSCHE BANK AG\ | 546,088 | $7.8M | 0.0% | 0.8% | -23.2% |
| 22 | NORTHERN TRUST CORP | 540,163 | $7.7M | 0.0% | 0.7% | -4.0% |
| 23 | ACUTA CAPITAL PARTNERS, LLC | 535,109 | $7.7M | 5.8% | 0.7% | +5.4% |
| 24 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 438,712 | $6.3M | 0.0% | 0.6% | +29.3% |
| 25 | DIADEMA PARTNERS LP | 421,107 | $6.0M | 0.8% | 0.6% | -26.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.